Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04883242 · ClinicalTrials.gov registry record · Phase 2

Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma

A Phase 2 study of Refractory Multiple Myeloma and Recurrent Multiple Myeloma, sponsored by University of Washington.

Active
Registry status
Phase 2
Development phase
30
Enrollment target
1
Study location

NCT04883242 is a Phase 2 study of Refractory Multiple Myeloma and Recurrent Multiple Myeloma that is active but no longer recruiting, run by University of Washington. The registered enrollment target is 30 participants, below the 48-participant average among 67 other Refractory Multiple Myeloma trials with a reported enrollment target (37% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04883242, a Phase 2 study of Refractory Multiple Myeloma and Recurrent Multiple Myeloma, is active but no longer recruiting, sponsored by University of Washington.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

This phase II trial studies the effect of isatuximab, carfilzomib, pomalidomide, and dexamethasone in treating patients with multiple myeloma that has come back (relapsed) or does not respond to treatment (refractory). Isatuximab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Carfilzomib may stop the growth of cancer cells by blocking some of the proteins needed for cell growth. Pomalidomide may help shrink or slow the growth of multiple myeloma. Anti-inflammatory drugs, such as dexamethasone lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Giving isatuximab, carfilzomib, pomalidomide, and dexamethasone may kill more cancer cells.

Conditions Studied

Refractory Multiple Myeloma Recurrent Multiple Myeloma

Interventions

  • PROCEDURE Bone Marrow Biopsy
  • DRUG Dexamethasone
  • DRUG Pomalidomide
  • DRUG Carfilzomib
  • BIOLOGICAL Isatuximab

Study Locations (1)

Washington

  • Fred Hutch/University of Washington Cancer Consortium - Seattle

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2021-07-29
Est. Completion 2031-12-31
Phase Phase 2

Sponsor

University of Washington

1,048 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04883242

The ClinicalTrials.gov registry entry for NCT04883242 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 48-participant average among 67 other Refractory Multiple Myeloma trials with a reported enrollment target (37% lower). The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Refractory Multiple Myeloma appearing as the primary indexed condition, and to 5 interventions - of which Bone Marrow Biopsy is the first listed.

NCT04883242 reports 1 study location spanning 1 distinct geographic area - top geographies include Washington.

Frequently Asked Questions

What is clinical trial NCT04883242 about?

NCT04883242 is a clinical study titled "Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma". This phase II trial studies the effect of isatuximab, carfilzomib, pomalidomide, and dexamethasone in treating patients with multiple myeloma that has come back (relapsed) or does not respond to treatment (refractory). Isatuximab is a monoclonal antibody that may interfere with the ability of cancer...

What is the current status of trial NCT04883242?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2021-07-29. Estimated completion is 2031-12-31.

What conditions does trial NCT04883242 study?

This clinical trial studies the following conditions: Refractory Multiple Myeloma, Recurrent Multiple Myeloma.

What interventions are being tested in trial NCT04883242?

The interventions under investigation include: Bone Marrow Biopsy (PROCEDURE), Dexamethasone (DRUG), Pomalidomide (DRUG), Carfilzomib (DRUG), Isatuximab (BIOLOGICAL).

Who is sponsoring clinical trial NCT04883242?

This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04883242 being conducted?

This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Refractory Multiple Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Refractory Multiple Myeloma

All registered trials for this condition

Recurrent Multiple Myeloma

All registered trials for this condition

Washington

All trials with a study site in Washington

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.